Literature DB >> 8288903

Inhibition of collagen lattice contraction by pentoxifylline and interferon-alpha, -beta, and -gamma.

M J Dans1, R Isseroff.   

Abstract

The ability to control wound contraction is important in preventing disfiguring scarring in burn and trauma patients. Fibroblasts within the wound generate the mechanical forces that cause this contraction, and their interactions with various extracellular matrix components are thought to regulate this process. Because pentoxifylline and the interferons are believed to moderate fibroblast production of such matrix components, we assessed the effects of these agents on wound contraction in vitro, using a model wherein dermal fibroblasts are incorporated into a collagen lattice. Pentoxifylline and interferon-alpha, -beta, and -gamma inhibited lattice contraction in a dose-dependent manner and showed no effect on cell number or cell viability. These results suggest that pentoxifylline and the interferons may retard wound contraction in vivo and thus reduce scarring associated with severely contracted wounds. Further study is needed to determine the mechanism of action of these agents on the collagen lattice model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288903     DOI: 10.1111/1523-1747.ep12371743

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Liposome associated interferon-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig.

Authors:  A Ghahary; E E Tredget; Q Shen; R T Kilani; P G Scott; M Takeuchi
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Di-rhamnolipid from Pseudomonas aeruginosa displays differential effects on human keratinocyte and fibroblast cultures.

Authors:  Tamara Stipcevic; Tihana Piljac; Roslyn R Isseroff
Journal:  J Dermatol Sci       Date:  2005-09-30       Impact factor: 4.563

3.  Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty.

Authors:  Gaetano Di Vita; Rosalia Patti; Pietro D'Agostino; Francesco Arcoleo; Giuseppe Caruso; Matteo Arcara; Valentina Davì; Enrico Cillari
Journal:  Langenbecks Arch Surg       Date:  2005-09-23       Impact factor: 3.445

4.  Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.

Authors:  C Raetsch; J D Jia; G Boigk; M Bauer; E G Hahn; E-O Riecken; D Schuppan
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

5.  Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.

Authors:  H Takagi; M S Ochoa; L Zhou; T Helfman; H Murata; V Falanga
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Physiological ER Stress Mediates the Differentiation of Fibroblasts.

Authors:  Shinsuke Matsuzaki; Toru Hiratsuka; Manabu Taniguchi; Kenta Shingaki; Tateki Kubo; Koichiro Kiya; Toshihiro Fujiwara; Shigeyuki Kanazawa; Ryutaro Kanematsu; Tameyasu Maeda; Hironori Takamura; Kohe Yamada; Ko Miyoshi; Ko Hosokawa; Masaya Tohyama; Taiichi Katayama
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

7.  Vitamin D Inhibits Expression and Activity of Matrix Metalloproteinase in Human Lung Fibroblasts (HFL-1) Cells.

Authors:  Seo Hwa Kim; Moon Seong Baek; Dong Sik Yoon; Jong Seol Park; Byoung Wook Yoon; Byoung Su Oh; Jinkyeong Park; Hui Jung Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-08-29

Review 8.  A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches.

Authors:  Emily E Limmer; Donald A Glass
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-23

9.  Evaluating the effects of pentoxifylline administration on experimental pressure sores in rats by biomechanical examinations.

Authors:  Kobra Velaei; Mohammad Bayat; Giti Torkman; Fatemealsadat Rezaie; Abdollah Amini; Mohsen Noruzian; Azaedh Tavassol; Mehernoush Bayat
Journal:  Lab Anim Res       Date:  2012-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.